跳至主要内容
临床试验/NCT04631263
NCT04631263已完成不适用

A Randomized, Evaluator-blinded, Parallel Group, no Treatment Controlled, Multi-center Study to Evaluate Effectiveness and Safety of GP0109 for Augmentation and Correction of Retrusion in the Chin Region

Galderma R&D10 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2021年1月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Galderma R&D
入组人数
140
试验地点
10
主要终点
Responder rate based on the Galderma Chin Retrusion Scale as assessed live by the Blinded Evaluator

研究概览

简要总结

Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GP0109 for augmentation and correction or retrusion in the chin region in Canada

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subject willing to comply with the requirements of the study
  • subject intent to receive treatment for augmentation and correction of retrusion in the chin region
  • subject with mild or moderate (grade 1 or 2) on the GCRS

排除标准

  • subjects presenting with know allergy to HA (hyaluronic acid) filler or amide local anesthetics
  • subjects with any previous facial surgery below the nasal line or previous HA filler or collagen below the nasal line within 12 months
  • subjects in any other interventional clinical study within 30 days before baseline

结局指标

主要结局

Responder rate based on the Galderma Chin Retrusion Scale as assessed live by the Blinded Evaluator

时间窗: 3 months after baseline

次要结局

未报告次要终点

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验